BNO has posted a report by H C Wainright & Co. The report rates the stock as a buy. Big price target estimate is provided and speaks about the oncology assets as business development products with the focus ever increasingly turning to BNC210 (probably quite rightly so). It's worth a look. I guess the analyst's price target of $2 is going to make most holders happy. GLTA